U.S. REITS Stock News

Carvana (NYSE:CVNA) and Root report more than 200,000 embedded Carvana Insurance policies sold through their exclusive digital partnership. The milestone reflects traction for fully online auto buying and insurance bundling within a single transaction flow. The collaboration focuses on integrating Root's insurance offering directly into Carvana's digital car retail experience. For readers following NYSE:CVNA, this insurance milestone sits at the intersection of online auto retail and...

Adobe (NasdaqGS:ADBE) has partnered with Tesco, the UK's largest food retailer, to expand the use of AI in personalized marketing. The collaboration will combine Adobe's AI and engineering capabilities with Tesco's Clubcard data to refine customer targeting and engagement. This agreement marks an extension of Adobe's AI platform into large scale retail customer data and marketing use cases. Adobe, with a current share price of $235.72, has seen negative returns over multiple periods,...

In recent weeks, Meta Platforms has rolled out its Muse Spark AI model across its apps, while expanding long-term AI infrastructure partnerships such as a US$21.00 billion CoreWeave deal and a multi-year Broadcom collaboration to support its in-house MTIA accelerator chips. At the same time, eMarketer now projects Meta to overtake Google in global digital ad revenue in 2026, underscoring how AI-driven automation and personalization are reshaping Meta’s core advertising franchise and its role...

Strategy Inc. (NasdaqGS:MSTR) is seeing a surge in trading activity in its STRC preferred stock, signaling growing investor focus on this part of its capital structure. The company continues to use preferred equity funding to support Bitcoin acquisitions, shifting a greater share of claims ahead of common shareholders. These changes in trading volume and financing mix are reshaping shareholder risk, liquidity considerations, and the role of preferred holders in the overall capital...

Stock move puts Phathom Pharmaceuticals in focus Recent trading in Phathom Pharmaceuticals (PHAT) has drawn fresh attention to the gastrointestinal drug developer, with investors weighing its current market value against the ongoing commercialization of VOQUEZNA therapies in the United States. See our latest analysis for Phathom Pharmaceuticals. At a share price of $12.67, recent trading has come after a 22.18% 1 month share price return but follows a 19.35% decline year to date and a 165.62%...

Earlier in April 2026, BioNTech and Duality Biologics reported positive primary Phase 2 data for their HER2-targeted antibody-drug conjugate trastuzumab pamirtecan in previously treated, advanced endometrial cancer, showing clinically meaningful response rates, progression-free survival of around eight months, and a manageable safety profile across all HER2 expression levels. Because the drug already holds FDA Fast Track and Breakthrough Therapy designations and is backed by ongoing Phase 3...

STAAR Surgical Company reported preliminary net sales of over US$90,000,000 for the first quarter ended April 3, 2026, compared with US$42,600,000 a year earlier. This sharp year-on-year increase in quarterly revenue highlights a significant step-change in the company’s recent commercial performance and operating momentum. We’ll now examine how this sharp year-on-year revenue increase could reshape STAAR Surgical’s investment narrative and future business expectations. We've uncovered the 12...

Plant closures put Tyson Foods (TSN) cost actions and demand pressures in focus Tyson Foods (TSN) has drawn fresh attention after deciding to shut its Hillshire Brands plant in Rome, Georgia, as part of a broader series of production closures tied to softer meat demand and higher prices. See our latest analysis for Tyson Foods. Shares now trade at US$64.96, with a 30 day share price return of 7.69% and a 1 year total shareholder return of 10.28%. This suggests momentum has been building even...

Hewlett Packard Enterprise (HPE) has drawn fresh attention after recent share price moves, with the stock showing a roughly 13% gain over the past month and about 11% over the past 3 months. See our latest analysis for Hewlett Packard Enterprise. Set against a 1 year total shareholder return of 67.14% and a 5 year total shareholder return of 79.79%, the recent 13.39% 30 day share price return suggests momentum has been building despite a softer 1 day move. If HPE’s recent move has you...

Wondering if Coupang at around US$20.72 is a bargain or just fairly priced? This article walks through what that number might really mean for you. The stock has returned 8.0% over the last 7 days and 12.3% over the last 30 days, while year to date it is at an 11.3% loss and the 1 year return sits at a 3.5% loss, compared with a 30.6% gain over 3 years and a 51.4% loss over 5 years. Recent headlines around Coupang have focused on its role as a major Korea based e commerce platform and how its...

Enphase Energy (ENPH) has put its commercial microinverter push in the spotlight by expanding shipments of its IQ9N-3P and IQ8P-3P units from U.S. facilities to meet installer demand and evolving regulation. See our latest analysis for Enphase Energy. The recent expansion of U.S.-made commercial microinverters comes after a period of weaker share price returns, with a 30-day share price return showing a 27.39% decline and a 1-year total shareholder return reflecting a 39.70% loss, which...

Recent Performance Snapshot Artisan Partners Asset Management (APAM) has recently drawn attention after a 2.6% move in the latest session, extending its gains over the past week and month while remaining lower across the past 3 months. See our latest analysis for Artisan Partners Asset Management. That recent 1-day share price return of 2.57% and 7-day share price return of 6.59% comes after a weaker patch. The 90-day share price return shows a 12.40% decline, while the 1-year total...

Lazard (LAZ) has drawn fresh attention after reporting preliminary assets under management of about US$259.2b as of March 31, 2026, alongside market and FX depreciation and modest net inflows. See our latest analysis for Lazard. The recent AUM update has arrived alongside a sharp short term rebound, with a 7 day share price return of 21.44% and 1 year total shareholder return of 45.61%. However, the 90 day share price return remains slightly negative, which suggests that momentum has only...

Agilent Technologies (A) is back in focus after two contrasting developments: the Supreme Court left rulings invalidating its CRISPR related patents in place, and the company introduced its new BioTek Cytation 9 cell imaging multimode reader. See our latest analysis for Agilent Technologies. At a share price of $120.39, investors have seen a 7.96% 1 month share price return and a 5.72% 7 day gain. However, the 90 day share price return of 17.50% and year to date share price return of 12.73%...

Datadog (DDOG) has expanded its observability platform with Datadog Experiments, a new tool that lets product teams run A/B tests and measure business impact directly alongside application performance and user behavior data. See our latest analysis for Datadog. Despite product launches like Datadog Experiments and upbeat commentary around AI related demand, the share price has a negative 17.34% year to date return and an 11.20% 1 month share price return. However, the 1 year total shareholder...

CRISPR Therapeutics (NasdaqGM:CRSP) reports accelerating sales momentum and market adoption for its approved gene editing therapy, Casgevy. The company holds nearly US$2b in cash, supporting investment in new programs across cardiovascular disease, cancers, and autoimmune disorders. Six clinical programs are scheduled for readouts over the next 6 to 12 months, marking an expansion beyond rare disease indications. For investors tracking gene editing, CRISPR Therapeutics sits at an important...

Energy shocks, sticky inflation and shifting central bank policies are keeping markets on edge, but they are also creating room for smaller, more focused companies to stand out. While headlines center on mega caps, some early-stage AI names in machine learning, automation and data intelligence are quietly building tools that could reshape how businesses cope with higher costs and supply disruptions. This article highlights 3 stocks from an AI Small Caps screener that targets these kinds of...

Investors may be wondering whether Intel's share price still reflects good value after a strong run, or whether the stock has already priced in much of its story. Intel's last close was US$63.81, with returns of 8.2% over 7 days, 39.4% over 30 days, 62.0% year to date, 231.8% over 1 year, and 109.9% over 3 years. This recent performance is front and center for anyone thinking about risk and reward. These moves have come alongside ongoing attention on Intel's role in semiconductors, AI...

Why First Industrial Realty Trust is on investors’ radar today First Industrial Realty Trust (FR) has drawn attention after recent trading, with investors weighing its current share price of US$61.10 against its recent return profile and underlying industrial real estate fundamentals. For context, this U.S. focused logistics REIT reports annual revenue of US$727.561 million and net income of US$247.297 million. Both figures are tied entirely to its industrial properties across major...

On April 8, 2026, FactSet Research Systems announced that CFO Helen Shan would step down and be succeeded by incoming CFO Joshua Warren, a finance leader with experience across asset management, financial technology and capital markets. At the same time, FactSet raised its fiscal 2026 earnings and revenue guidance, signaling confidence in its operations despite recent leadership changes and broader market uncertainty. Next, we'll examine how the appointment of Joshua Warren as CFO could...

Why Fair Isaac Stock Is Moving Now Fair Isaac (FICO) has come under pressure after a Barclays note reduced its price target, as investors react to ongoing regulatory questions around credit score pricing and broader weakness across software names. See our latest analysis for Fair Isaac. The share price has lost momentum over recent months, with a 30 day share price return of 10.96% and a 90 day share price return of 37.68%. This has contributed to a year to date decline of 38.70% and a 1 year...

Bausch + Lomb (BLCO) is drawing fresh attention after 510(k) clearance for new vitrectomy tools, a European launch for its enVista Envy intraocular lens, and extensive data presentations at the upcoming ASCRS ophthalmology meeting. See our latest analysis for Bausch + Lomb. These product updates come as Bausch + Lomb’s share price sits at $16.71, with a 7 day share price return of 4.96% and a 1 year total shareholder return of 40.07%. This suggests recent news is feeding into improving...

Kennametal: recent performance and business mix Kennametal (KMT) has been on the radar for investors after a mixed stretch of returns, with the stock down about 1% over the past day but showing gains over the past week and month. Over the past 3 months and year to date, Kennametal has recorded positive total returns, alongside a 1 year total return above 100%. For investors, that invites closer attention to what is driving the current pricing versus the underlying business. The company...

If you are wondering whether Fermi at US$5.28 is priced attractively or carrying more risk than reward, starting with a clear look at valuation can help you frame that question. Over the last week, the share price return is 6.9%. Over the past 30 days the return is a 33.7% decline and the year to date return is a 40.1% decline, which naturally raises questions about how the market is reassessing the stock. Recent coverage has focused on how Fermi fits within the specialized real estate space...